These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30045138)

  • 21. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
    Rauh-Hain JA; Foley OW; Winograd D; Andrade C; Clark RM; Vargas RJ; Hinchcliff EM; Esselen KM; Horowitz NS; del Carmen MG
    Am J Obstet Gynecol; 2015 May; 212(5):600.e1-8. PubMed ID: 25514761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications.
    Duska LR; Kohn EC
    Ann Oncol; 2017 Nov; 28(suppl_8):viii8-viii12. PubMed ID: 29232468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
    Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
    Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?
    Ataseven B; Harter P; Grimm C; Heitz F; Heikaus S; Traut A; Kahl A; Kurzeder C; Prader S; du Bois A
    Gynecol Oncol; 2016 Aug; 142(2):243-7. PubMed ID: 27208538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy.
    Tajik P; van de Vrie R; Zafarmand MH; Coens C; Buist MR; Vergote I; Bossuyt PMM; Kenter GG
    Int J Gynecol Cancer; 2018 Mar; 28(3):453-458. PubMed ID: 29324537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.
    Meinhold-Heerlein I; Fotopoulou C; Harter P; Kurzeder C; Mustea A; Wimberger P; Hauptmann S; Sehouli J
    Arch Gynecol Obstet; 2016 Apr; 293(4):695-700. PubMed ID: 26894303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging.
    Javadi S; Ganeshan DM; Qayyum A; Iyer RB; Bhosale P
    AJR Am J Roentgenol; 2016 Jun; 206(6):1351-60. PubMed ID: 27042752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].
    Lavoue V; Huchon C; Akladios C; Alfonsi P; Bakrin N; Ballester M; Bendifallah S; Bolze PA; Bonnet F; Bourgin C; Chabbert-Buffet N; Collinet P; Courbiere B; De la Motte Rouge T; Devouassoux-Shisheboran M; Falandry C; Ferron G; Fournier L; Gladieff L; Golfier F; Gouy S; Guyon F; Lambaudie E; Leary A; Lecuru F; Lefrere-Belda MA; Leblanc E; Lemoine A; Narducci F; Ouldamer L; Pautier P; Planchamp F; Pouget N; Ray-Coquard I; Rousset-Jablonski C; Senechal-Davin C; Touboul C; Thomassin-Naggara I; Uzan C; You B; Daraï E
    Bull Cancer; 2019 Apr; 106(4):354-370. PubMed ID: 30850152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer of the ovary, fallopian tube, and peritoneum.
    Berek JS; Kehoe ST; Kumar L; Friedlander M
    Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():59-78. PubMed ID: 30306591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan.
    Chao KC; Chen YJ; Juang CM; Lau HY; Wen KC; Sung PL; Fang FY; Twu NF; Yen MS
    Taiwan J Obstet Gynecol; 2013 Mar; 52(1):81-4. PubMed ID: 23548224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical and pathological features of borderline ovarian tumors].
    Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.
    Rochet N; Lindel K; Katayama S; Schubert K; Herfarth K; Schneeweiss A; Sohn C; Harms W; Debus J
    Strahlenther Onkol; 2015 Jul; 191(7):582-9. PubMed ID: 25786589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.
    Bamias A; Karadimou A; Soupos N; Sotiropoulou M; Zagouri F; Haidopoulos D; Thomakos N; Rodolakis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2011 Oct; 123(1):37-42. PubMed ID: 21764430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns and associated factors in patients with advanced epithelial ovarian cancer: a population-based study.
    Zijlstra M; Timmermans M; Fransen H; van der Aa M; Reyners A; Raijmakers N; van de Poll-Franse L
    Int J Gynecol Cancer; 2019 Jul; 29(6):1032-1037. PubMed ID: 31263022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.